Wednesday, 18 March 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 18 March 2026
News

Australia lines up for RNA first

Posted 18 March 2026 AM

Australia could be the first country in the world to approve SkyHawk Therapeutics’ RNA therapeutic ruxuplam for Huntingon’s disease (HD), after the TGA offered the company the provisional approval pathway.

The US based clinical-stage biotechnology company uses its proprietary platform, SKYSTAR, to discover and develop small molecular RNA modulating therapies for the world’s most intractable diseases. Ruxuplam, also known as SKY-0515, is the company’s lead drug candidate.

To see the whole article, please login

Popular

Novo CEO taps Australia to lead
12 drugs in PBS limbo pileup
CEO pay packet rockets by 75%
PBAC lets slip reason for 'go-slow'
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home